Drugs / UPANOVIMAB
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04483375 | Jul → Nov 2020 | COVID-19 | Sinocelltech Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05156645 | Jan → Dec 2022 | COVID-19 | Sinocelltech Ltd. | Withdrawn | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04709328 | Mar 2021 → Jan 2022 overdue | COVID-19 | Sinocelltech Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT04644185 | Mar → Dec 2021 | COVID-19 | Sinocelltech Ltd. | Terminated | No outcome recorded |
| Phase 2/3 | NCT04683328 | Feb → May 2021 | COVID-19 | Sinocelltech Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UPANOVIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802216 ↗ |
| Known as | SCTA01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04483375 ↗ |
| Modality | Monoclonal antibody | “recombinant humanized anti-SARS-CoV-2 monoclonal antibody” NCT04483375 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous (IV) infusion of SCTA01 at Treatment day 1.” NCT04683328 ↗ |